Cargando…
A Quinoxaline Derivative as a Potent Chemotherapeutic Agent, Alone or in Combination with Benznidazole, against Trypanosoma cruzi
BACKGROUND: Chagas’ disease is a condition caused by the protozoan Trypanosoma cruzi that affects millions of people, mainly in Latin America where it is considered endemic. The chemotherapy for Chagas disease remains a problem; the standard treatment currently relies on a single drug, benznidazole,...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894994/ https://www.ncbi.nlm.nih.gov/pubmed/24465654 http://dx.doi.org/10.1371/journal.pone.0085706 |
_version_ | 1782299919104606208 |
---|---|
author | Rodrigues, Jean Henrique da Silva Ueda-Nakamura, Tânia Corrêa, Arlene Gonçalves Sangi, Diego Pereira Nakamura, Celso Vataru |
author_facet | Rodrigues, Jean Henrique da Silva Ueda-Nakamura, Tânia Corrêa, Arlene Gonçalves Sangi, Diego Pereira Nakamura, Celso Vataru |
author_sort | Rodrigues, Jean Henrique da Silva |
collection | PubMed |
description | BACKGROUND: Chagas’ disease is a condition caused by the protozoan Trypanosoma cruzi that affects millions of people, mainly in Latin America where it is considered endemic. The chemotherapy for Chagas disease remains a problem; the standard treatment currently relies on a single drug, benznidazole, which unfortunately induces several side effects and it is not successful in the cure of most of the chronic patients. In order to improve the drug armamentarium against Chagas’ disease, in the present study we describe the synthesis of the compound 3-chloro-7-methoxy-2-(methylsulfonyl) quinoxaline (quinoxaline 4) and its activity, alone or in combination with benznidazole, against Trypanosoma cruzi in vitro. METHODOLOGY/PRINCIPAL FINDINGS: Quinoxaline 4 was found to be strongly active against Trypanosoma cruzi Y strain and more effective against the proliferative forms. The cytotoxicity against LLCMK(2) cells provided selective indices above one for all of the parasite forms. The drug induced very low hemolysis, but its anti-protozoan activity was partially inhibited when mouse blood was added in the experiment against trypomastigotes, an effect that was specifically related to blood cells. A synergistic effect between quinoxaline 4 and benznidazole was observed against epimastigotes and trypomastigotes, accompanied by an antagonistic interaction against LLCMK(2) cells. Quinoxaline 4 induced several ultrastructural alterations, including formations of vesicular bodies, profiles of reticulum endoplasmic surrounding organelles and disorganization of Golgi complex. These alterations were also companied by cell volume reduction and maintenance of cell membrane integrity of treated-parasites. CONCLUSION/SIGNIFICANCE: Our results demonstrated that quinoxaline 4, alone or in combination with benznidazole, has promising effects against all the main forms of T. cruzi. The compound at low concentrations induced several ultrastructural alterations and led the parasite to an autophagic-like cell death. Taken together these results may support the further development of a combination therapy as an alternative more effective in Chagas’ disease treatment. |
format | Online Article Text |
id | pubmed-3894994 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-38949942014-01-24 A Quinoxaline Derivative as a Potent Chemotherapeutic Agent, Alone or in Combination with Benznidazole, against Trypanosoma cruzi Rodrigues, Jean Henrique da Silva Ueda-Nakamura, Tânia Corrêa, Arlene Gonçalves Sangi, Diego Pereira Nakamura, Celso Vataru PLoS One Research Article BACKGROUND: Chagas’ disease is a condition caused by the protozoan Trypanosoma cruzi that affects millions of people, mainly in Latin America where it is considered endemic. The chemotherapy for Chagas disease remains a problem; the standard treatment currently relies on a single drug, benznidazole, which unfortunately induces several side effects and it is not successful in the cure of most of the chronic patients. In order to improve the drug armamentarium against Chagas’ disease, in the present study we describe the synthesis of the compound 3-chloro-7-methoxy-2-(methylsulfonyl) quinoxaline (quinoxaline 4) and its activity, alone or in combination with benznidazole, against Trypanosoma cruzi in vitro. METHODOLOGY/PRINCIPAL FINDINGS: Quinoxaline 4 was found to be strongly active against Trypanosoma cruzi Y strain and more effective against the proliferative forms. The cytotoxicity against LLCMK(2) cells provided selective indices above one for all of the parasite forms. The drug induced very low hemolysis, but its anti-protozoan activity was partially inhibited when mouse blood was added in the experiment against trypomastigotes, an effect that was specifically related to blood cells. A synergistic effect between quinoxaline 4 and benznidazole was observed against epimastigotes and trypomastigotes, accompanied by an antagonistic interaction against LLCMK(2) cells. Quinoxaline 4 induced several ultrastructural alterations, including formations of vesicular bodies, profiles of reticulum endoplasmic surrounding organelles and disorganization of Golgi complex. These alterations were also companied by cell volume reduction and maintenance of cell membrane integrity of treated-parasites. CONCLUSION/SIGNIFICANCE: Our results demonstrated that quinoxaline 4, alone or in combination with benznidazole, has promising effects against all the main forms of T. cruzi. The compound at low concentrations induced several ultrastructural alterations and led the parasite to an autophagic-like cell death. Taken together these results may support the further development of a combination therapy as an alternative more effective in Chagas’ disease treatment. Public Library of Science 2014-01-17 /pmc/articles/PMC3894994/ /pubmed/24465654 http://dx.doi.org/10.1371/journal.pone.0085706 Text en © 2014 Rodrigues et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Rodrigues, Jean Henrique da Silva Ueda-Nakamura, Tânia Corrêa, Arlene Gonçalves Sangi, Diego Pereira Nakamura, Celso Vataru A Quinoxaline Derivative as a Potent Chemotherapeutic Agent, Alone or in Combination with Benznidazole, against Trypanosoma cruzi |
title | A Quinoxaline Derivative as a Potent Chemotherapeutic Agent, Alone or in Combination with Benznidazole, against Trypanosoma cruzi
|
title_full | A Quinoxaline Derivative as a Potent Chemotherapeutic Agent, Alone or in Combination with Benznidazole, against Trypanosoma cruzi
|
title_fullStr | A Quinoxaline Derivative as a Potent Chemotherapeutic Agent, Alone or in Combination with Benznidazole, against Trypanosoma cruzi
|
title_full_unstemmed | A Quinoxaline Derivative as a Potent Chemotherapeutic Agent, Alone or in Combination with Benznidazole, against Trypanosoma cruzi
|
title_short | A Quinoxaline Derivative as a Potent Chemotherapeutic Agent, Alone or in Combination with Benznidazole, against Trypanosoma cruzi
|
title_sort | quinoxaline derivative as a potent chemotherapeutic agent, alone or in combination with benznidazole, against trypanosoma cruzi |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894994/ https://www.ncbi.nlm.nih.gov/pubmed/24465654 http://dx.doi.org/10.1371/journal.pone.0085706 |
work_keys_str_mv | AT rodriguesjeanhenriquedasilva aquinoxalinederivativeasapotentchemotherapeuticagentaloneorincombinationwithbenznidazoleagainsttrypanosomacruzi AT uedanakamuratania aquinoxalinederivativeasapotentchemotherapeuticagentaloneorincombinationwithbenznidazoleagainsttrypanosomacruzi AT correaarlenegoncalves aquinoxalinederivativeasapotentchemotherapeuticagentaloneorincombinationwithbenznidazoleagainsttrypanosomacruzi AT sangidiegopereira aquinoxalinederivativeasapotentchemotherapeuticagentaloneorincombinationwithbenznidazoleagainsttrypanosomacruzi AT nakamuracelsovataru aquinoxalinederivativeasapotentchemotherapeuticagentaloneorincombinationwithbenznidazoleagainsttrypanosomacruzi AT rodriguesjeanhenriquedasilva quinoxalinederivativeasapotentchemotherapeuticagentaloneorincombinationwithbenznidazoleagainsttrypanosomacruzi AT uedanakamuratania quinoxalinederivativeasapotentchemotherapeuticagentaloneorincombinationwithbenznidazoleagainsttrypanosomacruzi AT correaarlenegoncalves quinoxalinederivativeasapotentchemotherapeuticagentaloneorincombinationwithbenznidazoleagainsttrypanosomacruzi AT sangidiegopereira quinoxalinederivativeasapotentchemotherapeuticagentaloneorincombinationwithbenznidazoleagainsttrypanosomacruzi AT nakamuracelsovataru quinoxalinederivativeasapotentchemotherapeuticagentaloneorincombinationwithbenznidazoleagainsttrypanosomacruzi |